Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders

Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders: Randomised Controlled Trial

The aim of this study is to test the effect of cognitive stimulation (CS), applied individually and at home, on the overall cognitive functioning, emotional state, functionality, and quality of life (QoL) in adults with psychotic disorders. To this end, a randomised controlled clinical trial will be conducted in which selected participants will be randomly assigned to an individual intervention group using CS or a control group. The CS program is adapted from other existing protocol, composed of 32 sessions. Each session will last 45 minutes and will be held twice weekly. There will be four evaluation points (baseline, intra-evaluation - after 8 weeks of intervention, post-evaluation - after 16 weeks of intervention, follow-up - after 8 weeks of the end of intervention).

Study Overview

• Status: Completed
• Conditions: Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Delusional Disorder; Substance-Induced Psychotic Disorder
• Intervention / Treatment: Behavioral: Individual cognitive stimulation therapy (iCST)

Detailed Description

Epidemiological studies indicate that Portugal has one of the highest prevalence rates of mental disorders in Europe. In 2016, one in five Portuguese suffered from a psychiatric illness and the network of Integrated Continuous Care in mental health is small, which is a major constraint to rehabilitation and support responses for people with mental health problems.

It is important to include psychologists and neuropsychologists in multidisciplinary teams, in actions related to mental health promotion and mental illness prevention programs, so that they can provide more comprehensive interventions for other effects of chronic mental health conditions, such as cognitive decline.

There is evidence linking psychotic disorders to impairments in functioning in most cognitive domains, including memory, executive functions, and attention, and that cognitive ageing in some areas may be accelerated in individuals with psychotic disorders. Thus, it is important to focus interventions on cognitive functioning in patients with psychosis, even after acute psychotic symptoms have improved. Executive functions appear to be of particular importance in the context of mental health problems, as they appear to be particularly integral for psychosocial functioning and the completion of instrumental activities of daily living. There is evidence that CS interventions in individual format are associated with greater effectiveness.

Many studies have supported the effectiveness and accessibility of home-based interventions in people with chronic mental illness. Yet, there are few published studies on continuous intervention in people with chronic mental illness and even more limited knowledge of how cognitive stimulation can help chronic mental health patients, including those with psychosis, to function.

One Portuguese study about the effect of an individual CS program in a home setting on cognitive and mood functioning in adults with psychotic disorders was tested, showed encouraging results and presented in detail an intervention protocol. However, it also presents some important limitations (e.g., convenience sample, lack of follow-up evaluation).

This study aims to overcome those limitations, through a randomised controlled trial, and, in addition to testing the effect of the CS program on global cognition, it also aims to assess its effect on emotional state, daily functioning, and quality of life.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Portugal
  • Aveiro
    • Albergaria-a-Velha, Aveiro, Portugal, 3850-705
      • Cediara - Social Solidarity Association of Ribeira de Fráguas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 64 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adults under 65 years.
• Diagnosed with of schizophrenia spectrum and other psychotic disorders according to the criteria of DSM-5 (APA, 2013), determined by a professional clinician.
• Willing to participate in all intervention and assessment sessions.
• Provided informed consent.
• Native speakers of Portuguese.

Exclusion Criteria:

• Presentation of a condition requiring immediate intervention (e.g., suicidal thoughts).
• Severe sensory and physical limitations that prevent participation in the sessions.
• Severe disconnection with the environment and very limited attentional level.
• Inability to communicate adequately.
• Psychoactive substance use.
• Currently participating in another study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Group; Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.	Behavioral: Individual cognitive stimulation therapy (iCST); The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
No Intervention: Control Group; Participants assigned to the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed psychotic-specific medication.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cognitive functioning evaluated through Montreal Cognitive Assessment [MoCA]	Cognitive functioning is assessed using the MoCA which is a brief cognitive screening. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.	baseline
Change in cognitive functioning evaluated through MoCA	Cognitive functioning is assessed using the MoCA which is a brief cognitive screening. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.	8 weeks after the beginning of the intervention
Change in cognitive functioning evaluated through MoCA	Cognitive functioning is assessed using the MoCA which is a brief cognitive screening. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.	16 weeks after the beginning of the intervention
Change in cognitive functioning evaluated through MoCA	Cognitive functioning is assessed using the MoCA which is a brief cognitive screening. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.	8 weeks after end of intervention
Executive functions evaluated through Frontal Assessment Battery (FAB)	The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.	baseline
Change in executive functions evaluated through FAB	The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.	8 weeks after the beginning of the intervention
Change in executive functions evaluated through FAB	The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.	16 weeks after the beginning of the intervention
Change in executive functions evaluated through FAB	The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.	8 weeks after end of intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Self-maintaining and instrumental activities of daily living evaluated through Lawton Instrumental Activities of Daily Living (IADL) Scale	Lawton IADL Scale assesses level of independence of the elderly in relation to instrumental activities of daily living. A score is assigned according to the subject's ability to perform a given task. The score ranges between 8 and 30 points. The highest score corresponds to a higher degree of dependence.	baseline
Change in self-maintaining and instrumental activities of daily living evaluated through Lawton IADL Scale	Lawton IADL Scale assesses level of independence of the elderly in relation to instrumental activities of daily living. A score is assigned according to the subject's ability to perform a given task. The score ranges between 8 and 30 points. The highest score corresponds to a higher degree of dependence.	8 weeks after the beginning of the intervention
Change in self-maintaining and instrumental activities of daily living evaluated through Lawton IADL Scale	Lawton IADL Scale assesses level of independence of the elderly in relation to instrumental activities of daily living. A score is assigned according to the subject's ability to perform a given task. The score ranges between 8 and 30 points. The highest score corresponds to a higher degree of dependence.	16 weeks after the beginning of the intervention
Change in self-maintaining and instrumental activities of daily living evaluated through Lawton IADL Scale	Lawton IADL Scale assesses level of independence of the elderly in relation to instrumental activities of daily living. A score is assigned according to the subject's ability to perform a given task. The score ranges between 8 and 30 points. The highest score corresponds to a higher degree of dependence.	8 weeks after end of intervention
Depressive symptomatology assessed through the Center for Epidemiologic Studies Depression Scale (CES-D)	This instrument evaluated depressive symptoms using 20 answers. Scores range between 0 and 60 points. Higher scores indicate more severe depressive symptoms.	baseline
Change in depressive symptomatology assessed through the CES-D	This instrument evaluated depressive symptoms using 20 answers. Scores range between 0 and 60 points. Higher scores indicate more severe depressive symptoms.	8 weeks after the beginning of the intervention
Change in depressive symptomatology assessed through the CES-D	This instrument evaluated depressive symptoms using 20 answers. Scores range between 0 and 60 points. Higher scores indicate more severe depressive symptoms.	16 weeks after the beginning of the intervention
Change in depressive symptomatology assessed through the CES-D	This instrument evaluated depressive symptoms using 20 answers. Scores range between 0 and 60 points. Higher scores indicate more severe depressive symptoms.	8 weeks after end of intervention
Quality of life (QoL) evaluated through World Health Organization Quality of Life-Bref (WHOQOL-BREF)	The WHOQOL-BREF is used to assess QoL. Consisting of 26 items, it assesses several domains: physical health, mental health, social relationships and environment. The first 2 items are intended to assess the individual's perception of his/her general QoL and general health. The global score range between 0 to 100. Higher scores indicate better QoL perceived by the subject.	baseline
Change in QoL evaluated through WHOQOL-BREF	The WHOQOL-BREF is used to assess QoL. Consisting of 26 items, it assesses several domains: physical health, mental health, social relationships and environment. The first 2 items are intended to assess the individual's perception of his/her general QoL and general health. The global score range between 0 to 100. Higher scores indicate better QoL perceived by the subject.	8 weeks after the beginning of the intervention
Change in QoL evaluated through WHOQOL-BREF	The WHOQOL-BREF is used to assess QoL. Consisting of 26 items, it assesses several domains: physical health, mental health, social relationships and environment. The first 2 items are intended to assess the individual's perception of his/her general QoL and general health. The global score range between 0 to 100. Higher scores indicate better QoL perceived by the subject.	16 weeks after the beginning of the intervention
Change in QoL evaluated through WHOQOL-BREF	The WHOQOL-BREF is used to assess QoL. Consisting of 26 items, it assesses several domains: physical health, mental health, social relationships and environment. The first 2 items are intended to assess the individual's perception of his/her general QoL and general health. The global score range between 0 to 100. Higher scores indicate better QoL perceived by the subject.	8 weeks after end of intervention
Quality of life (QoL) evaluated through MOS Short Form Health Survey 36 Item v2 (SF-36v2)	The SF-36v2 is used to assess QoL. Consisting of 36 items, it assesses eight dimensions of health (dimensions of health (physical, performance limitations due to physical or emotional problems, intensity and discomfort due to pain, general health, vitality, social function and mental health). The global score range between 0 to 100. Higher scores indicate better the health-related QoL.	baseline
Change in QoL evaluated through SF-36v2	The SF-36v2 is used to assess QoL. Consisting of 36 items, it assesses eight dimensions of health (dimensions of health (physical, performance limitations due to physical or emotional problems, intensity and discomfort due to pain, general health, vitality, social function and mental health). The global score range between 0 to 100. Higher scores indicate better the health-related QoL.	8 weeks after the beginning of the intervention
Change in QoL evaluated through SF-36v2	The SF-36v2 is used to assess QoL. Consisting of 36 items, it assesses eight dimensions of health (dimensions of health (physical, performance limitations due to physical or emotional problems, intensity and discomfort due to pain, general health, vitality, social function and mental health). The global score range between 0 to 100. Higher scores indicate better the health-related QoL.	16 weeks after the beginning of the intervention
Change in QoL evaluated through SF-36v2	The SF-36v2 is used to assess QoL. Consisting of 36 items, it assesses eight dimensions of health (dimensions of health (physical, performance limitations due to physical or emotional problems, intensity and discomfort due to pain, general health, vitality, social function and mental health). The global score range between 0 to 100. Higher scores indicate better the health-related QoL.	8 weeks after end of intervention

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sociodemographic information gathered through the sociodemographic questionnaire	Participants' answers in the sociodemographic questionnaire designed specifically for this study. It gathers information about gender, age, marital status, educational level, clinical diagnosis and will be administered to all participants.	baseline

Collaborators and Investigators

• Sponsor: CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas
• Investigators: Principal Investigator: Susana I Justo Henriques, Ph.D., Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra; Principal Investigator: Ana E Marques Castro, M.Sc., Cediara - Associação de Solidariedade Social de Ribeira de Fráguas; Principal Investigator: Enrique Pérez Sáez, Ph.D., National Reference Centre for Alzheimer's and Dementia Care, Imserso, Spain; Principal Investigator: Janessa O Carvalho, Ph.D., Bridgewater State University, Bridgewater, USA; Principal Investigator: Ana P Sargaço Mendes, MD, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2021
• Primary Completion (Actual): October 22, 2021
• Study Completion (Actual): December 31, 2021

Study Registration Dates

• First Submitted: March 1, 2021
• First Submitted That Met QC Criteria: March 3, 2021
• First Posted (Actual): March 5, 2021

Study Record Updates

• Last Update Posted (Actual): March 10, 2022
• Last Update Submitted That Met QC Criteria: March 8, 2022
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: quality of life; cognition; schizophrenia; randomised controlled trial; mood; psychotic disorders; executive functions; non-pharmacological therapy; cognitive stimulation
• Additional Relevant MeSH Terms: Pathologic Processes; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Disease; Psychotic Disorders; Mental Disorders; Shared Paranoid Disorder; Schizophrenia, Paranoid
• Other Study ID Numbers: 20210218

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No